Boehringer Ingelheim to expand biopharma production at Vienna site

German family-owned pharma major Boehringer Ingelheim has said it will make a significant investment in biopharmaceutical production at its Vienna, Austria, site.

There the research-driven pharmaceutical company will establish a new large-scale biopharmaceutical production facility for active ingredients manufactured using cell cultures. With the roughly a 500 million-euro ($540 million) investment, Boehringer Ingelheim will also create more than 400 new jobs in the Austrian capital. The exact investment and job numbers will be established as details are ironed out.

“This is a decision for Europe as a pharma location,” said Andreas Barner, chairman of the board of managing directors at Boehringer Ingelheim. “We took a close look at various international options as part of the investment decision, also considering the research environment at potential sites. The clincher for Vienna was ultimately the company’s desire to additionally secure the market supply of biopharmaceutical products and to balance the risk by establishing a further independent facility,” Prof Barner explained.